

Kidney Transplant Rejection R&D Pipeline Analysis Report, Q4 2020

https://marketpublishers.com/r/KFEFEB2A07A8EN.html

Date: October 2020

Pages: 154

Price: US\$ 2,199.00 (Single User License)

ID: KFEFEB2A07A8EN

Abstracts

Kidney Transplant Rejection Pipeline Overview

The Q4 Kidney Transplant Rejection pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Kidney Transplant Rejection, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Kidney Transplant Rejection Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Kidney Transplant Rejection disease overview, Kidney Transplant Rejection types, Kidney Transplant Rejection symptoms, causes, and FDA/EMA approved treatment options.

Kidney Transplant Rejection Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Kidney Transplant Rejection indication. The report presents near-term and long-term pipeline development trends and potential insights.

Kidney Transplant Rejection Company Trends and Insights
The report analyzes the development progress, current status, investments,
partnerships, and other developments of 30 companies. Business profiles and contact
details of the companies actively perusing Kidney Transplant Rejection pipeline are
assessed.

Kidney Transplant Rejection R&D Pipeline Development Phase Trends and Insights



From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Kidney Transplant Rejection discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Kidney Transplant Rejection companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Kidney Transplant Rejection pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Kidney Transplant Rejection Pipeline Market News and Developments during 2020 The Kidney Transplant Rejection industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Kidney Transplant Rejection Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Kidney Transplant Rejection pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new



molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

30 companies are included including AlphaMab Co Ltd, Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Corline Biomedical AB, Gilead Sciences Inc, Hansa Medical AB, Helocyte Biosciences Inc, Hillhurst Biopharmaceuticals Inc, Idogen AB, ITB Med AB, JN Biosciences LLC, Kiniksa Pharmaceuticals Ltd, Kyowa Hakko Kirin Co Ltd, Mabtech Ltd, Medeor Therapeutics Inc, MyeloRx LLC, Nekonal Sarl, NextCell Pharma AB, Novartis AG, OSE Immunotherapeutics, Pharmicell Co Ltd, Talaris Therapeutics Inc, TolerogenixX GmbH, Tract Therapeutics Inc, TxCell SA, Veloxis Pharmaceuticals AS, Viela Bio Inc, Xenothera,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Kidney Transplant Rejection pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition



opportunities

Develop new candidates based on most focused targets and mechanism of actions



Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. KIDNEY TRANSPLANT REJECTION PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Kidney Transplant Rejection Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Kidney Transplant Rejection Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Kidney Transplant Rejection pipeline
- 2.5 Active Companies Developing Kidney Transplant Rejection pipeline

3. KIDNEY TRANSPLANT REJECTION DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. KIDNEY TRANSPLANT REJECTION PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

4.1 AlphaMab Co Ltd

Amgen Inc

Amyndas Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Corline Biomedical AB

Gilead Sciences Inc

Hansa Medical AB

Helocyte Biosciences Inc

Hillhurst Biopharmaceuticals Inc

Idogen AB

ITB Med AB

JN Biosciences LLC



Kiniksa Pharmaceuticals Ltd

Kyowa Hakko Kirin Co Ltd

Mabtech Ltd

Medeor Therapeutics Inc

MyeloRx LLC

Nekonal Sarl

NextCell Pharma AB

Novartis AG

OSE Immunotherapeutics

Pharmicell Co Ltd

Talaris Therapeutics Inc

TolerogenixX GmbH

Tract Therapeutics Inc

TxCell SA

Veloxis Pharmaceuticals AS

Viela Bio Inc

Xenothera

5. KIDNEY TRANSPLANT REJECTION PIPELINE DRUG PROFILES

- 5.1 Current Status of Drug and Vaccine Candidates
- 5.2 Drug Snapshot
 - 5.2.1 Drug
 - 5.2.2 Mechanism of Action
 - 5.2.3 Phase
 - 5.2.4 Co-Developer
 - 5.2.5 Originator
 - 5.2.6 Synonym
 - 5.2.7 Route of Administration
 - 5.2.8 Type of Molecule
 - 5.2.9 Orphan Drug Status
 - 5.2.10 New Molecular Entity
 - 5.2.11 Area
- 5.3 Drug Details
- 5.4 Mechanism of Action
- 5.5 Licensing/Collaboration Agreements
- 5.6 Clinical Trial Details

6. KIDNEY TRANSPLANT REJECTION PIPELINE MARKET NEWS AND



DEVELOPMENTS DURING 2020

7. APPENDIX

- 7.1 About the Publisher
- 7.2 Sources and Research Methodology



I would like to order

Product name: Kidney Transplant Rejection R&D Pipeline Analysis Report, Q4 2020

Product link: https://marketpublishers.com/r/KFEFEB2A07A8EN.html

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/KFEFEB2A07A8EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970